Two Seas Capital’s Tourmaline Bio TRML Stock Holding History

Two Seas Capital’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-21,891	Closed	-$501K	–	21
2024 Q1	$501K	Buy	+21,891	New	+$772K	0.1%	17

Other funds holding TRML

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Two Seas Capital's TRML Position: Q2 2024 in Review

Two Seas Capital sold out of Tourmaline Bio (TRML) in Q2 2024, closing a stake of 21,891 shares — an estimated $501K sold.

Two Seas Capital first reported a position in TRML in Q1 2024 and held it in 1 quarter. The position peaked at $501K in Q1 2024. 84 funds tracked by Wall St. Rank hold TRML as of Q2 2024.

Two Seas Capital reported no remaining Tourmaline Bio position as of Q2 2024 after selling out during the quarter.
Two Seas Capital sold 21,891 Tourmaline Bio shares in Q2 2024, an estimated $501K.
Two Seas Capital first reported a position in Tourmaline Bio in Q1 2024 and held it in 1 quarter.
Two Seas Capital's Tourmaline Bio position peaked at $501K in Q1 2024.
84 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2024.

Based on Two Seas Capital's 13F filing for Q2 2024, filed 14 Aug 2024.